Kura Oncology to Participate in Two Upcoming Investor Conferences
March 06, 2019 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, March 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Reports Fourth Quarter and Full Year 2018 Financial Results
March 05, 2019 16:03 ET
|
Kura Oncology, Inc.
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC underway – – Data from three ongoing Phase 2 trials of tipifarnib anticipated this year – – Third drug candidate menin-MLL inhibitor...
Kura Oncology to Report Fourth Quarter and Full Year 2018 Financial Results
February 26, 2019 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Present at SVB Leerink Global Healthcare Conference
February 20, 2019 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression
January 18, 2019 10:00 ET
|
Kura Oncology, Inc.
– Tipifarnib is a CXCL12 pathway inhibitor that may provide clinical benefit in subsets of patients with pancreatic cancer – – Analysis of a previously conducted, randomized Phase 3 trial reveals...
Kura Oncology to Present at J.P. Morgan Healthcare Conference
January 03, 2019 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma
December 02, 2018 12:00 ET
|
Kura Oncology, Inc.
– Two CRs, four PRs (46% ORR) observed in advanced AITL patients in Phase 2 trial of tipifarnib in PTCL – – AITL and other PTCL patients with high CXCL12 expression experienced 50% ORR and 90%...
Kura Oncology Announces New Patent for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma
November 28, 2018 07:30 ET
|
Kura Oncology, Inc.
– AITL patent expands protection for tipifarnib, provides exclusivity in U.S. to 2037 – – Prospective data from AITL and CXCL12+ cohorts in Phase 2 trial of tipifarnib in PTCL upcoming at ASH 2018 – ...
Kura Oncology Adds Commercial Veteran Mary Szela to Board of Directors
November 08, 2018 07:30 ET
|
Kura Oncology, Inc.
Ms. Szela brings expertise in global brand development to Kura as company enters first registration-directed trial SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a...
Kura Oncology to Participate in Two Upcoming Investor Conferences
November 06, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...